J&J Describes Eprex Safety Findings In Petition Against Follow-On Biologics

Johnson & Johnson believes that safety issues triggered by a change in stabilizers used in production of the erythropoietin Eprex support the biotechnology industry's position that "follow-on" biologics need separate clinical trials